The low probability of SARS-CoV-2 infection among these patients (<1%) supports the continuation of most oncologic treatments in the adjuvant and metastatic setting. Based on the present data, delaying active antitumor treatment to avoid SARS-CoV-2 transmission should not be routinely recommended.
